纵向血清转换面板显示接种mRNA-1273(现代)疫苗后6.5个月的抗sars - cov -2抗体水平

IF 0.5 Q4 HEMATOLOGY

Plasmatology Pub Date : 2022-01-01 DOI:10.1177/26348535221129232

F. Belda, Oscar Mora, Rebecca Christie, M. Crowley

{"title":"纵向血清转换面板显示接种mRNA-1273(现代)疫苗后6.5个月的抗sars - cov -2抗体水平","authors":"F. Belda, Oscar Mora, Rebecca Christie, M. Crowley","doi":"10.1177/26348535221129232","DOIUrl":null,"url":null,"abstract":"BACKGROUND Vaccines have emerged as a crucial tool in combatting the COVID-19 pandemic particularly those based on SARS-CoV-2 S-protein mRNA. A crucial aspect of vaccine efficacy is the duration of antibody responses. In this study, a seroconversion panel was created to assess antibody responses to the mRNA-1273 vaccine over time (6.5 months). METHODS Blood samples collected from 15 healthy adult participants prior to and up to 6.5 months after vaccination with the mRNA-1273 vaccine (Moderna). Serum from these blood samples were analyzed for anti-SARS-CoV-2 antibody activity by chemiluminescent immunoassay. RESULTS The immunoassay results showed that one participant was positive for anti-SARS-CoV-2 antibodies prior to vaccination indicating a prior infection. All participants showed a positive antibody response after the first vaccination. Highest antibody responses were seen after the second dose (41-45 days from the first dose). Subsequent samples collected at 69-75 days, 130-135 days, and 221-229 days after the first vaccination showed positive responses but a biphasic decline in the levels of anti-SARS-CoV-2 antibodies. CONCLUSIONS Declining antibody levels in these participants support the use of booster vaccination to increase antibody levels 4-6 months after the initial vaccine series and continued monitoring to assess the durability of COVID-19 vaccine responses. These results are in agreement with other studies showing antibody persistence but declining the antibody levels in the months after immunization with mRNA-based vaccines. The seroconversion panels described here could be useful in the development of antibody assays and in the assessment of the duration of antibody responses to vaccine boosters compared to the initial vaccine series. This panel could also be used to assess antibody activity against emerging viral variants (eg B.1.1.529 [Omicron] and its subvariants) compared to earlier variants.","PeriodicalId":29816,"journal":{"name":"Plasmatology","volume":"2 1","pages":""},"PeriodicalIF":0.5000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"A Longitudinal Seroconversion Panel Shows Anti-SARS-CoV-2 Antibody Levels up to 6.5 Months After Vaccination with mRNA-1273 (Moderna)\",\"authors\":\"F. Belda, Oscar Mora, Rebecca Christie, M. Crowley\",\"doi\":\"10.1177/26348535221129232\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"BACKGROUND Vaccines have emerged as a crucial tool in combatting the COVID-19 pandemic particularly those based on SARS-CoV-2 S-protein mRNA. A crucial aspect of vaccine efficacy is the duration of antibody responses. In this study, a seroconversion panel was created to assess antibody responses to the mRNA-1273 vaccine over time (6.5 months). METHODS Blood samples collected from 15 healthy adult participants prior to and up to 6.5 months after vaccination with the mRNA-1273 vaccine (Moderna). Serum from these blood samples were analyzed for anti-SARS-CoV-2 antibody activity by chemiluminescent immunoassay. RESULTS The immunoassay results showed that one participant was positive for anti-SARS-CoV-2 antibodies prior to vaccination indicating a prior infection. All participants showed a positive antibody response after the first vaccination. Highest antibody responses were seen after the second dose (41-45 days from the first dose). Subsequent samples collected at 69-75 days, 130-135 days, and 221-229 days after the first vaccination showed positive responses but a biphasic decline in the levels of anti-SARS-CoV-2 antibodies. CONCLUSIONS Declining antibody levels in these participants support the use of booster vaccination to increase antibody levels 4-6 months after the initial vaccine series and continued monitoring to assess the durability of COVID-19 vaccine responses. These results are in agreement with other studies showing antibody persistence but declining the antibody levels in the months after immunization with mRNA-based vaccines. The seroconversion panels described here could be useful in the development of antibody assays and in the assessment of the duration of antibody responses to vaccine boosters compared to the initial vaccine series. This panel could also be used to assess antibody activity against emerging viral variants (eg B.1.1.529 [Omicron] and its subvariants) compared to earlier variants.\",\"PeriodicalId\":29816,\"journal\":{\"name\":\"Plasmatology\",\"volume\":\"2 1\",\"pages\":\"\"},\"PeriodicalIF\":0.5000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Plasmatology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/26348535221129232\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Plasmatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/26348535221129232","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 2

摘要

疫苗已成为抗击COVID-19大流行的关键工具，特别是基于SARS-CoV-2 s蛋白mRNA的疫苗。疫苗效力的一个关键方面是抗体反应的持续时间。在这项研究中，建立了一个血清转换小组来评估抗体对mRNA-1273疫苗在一段时间内(6.5个月)的反应。方法采集15名健康成人受试者在接种mRNA-1273疫苗(Moderna)前和接种后6.5个月的血液样本。用化学发光免疫分析法分析这些血样的血清抗sars - cov -2抗体活性。结果免疫分析结果显示，一名参与者在接种疫苗前抗sars - cov -2抗体阳性，表明既往感染。所有参与者在第一次接种疫苗后均表现出阳性抗体反应。第二次给药后(第一次给药后41-45天)抗体应答最高。在第一次接种后69-75天、130-135天和221-229天收集的后续样本显示出阳性反应，但抗sars - cov -2抗体水平呈双期下降。结论:这些参与者抗体水平的下降支持在初始疫苗系列接种后4-6个月使用加强疫苗来提高抗体水平，并继续监测以评估COVID-19疫苗反应的持久性。这些结果与其他研究一致，表明抗体持续存在，但在接种基于mrna的疫苗后的几个月内抗体水平下降。这里描述的血清转换小组在开发抗体测定和评估与初始疫苗系列相比，抗体对疫苗增强剂的反应持续时间方面可能是有用的。该小组还可用于评估与早期变体相比，针对新出现的病毒变体(例如B.1.1.529 [Omicron]及其亚变体)的抗体活性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

A Longitudinal Seroconversion Panel Shows Anti-SARS-CoV-2 Antibody Levels up to 6.5 Months After Vaccination with mRNA-1273 (Moderna)

BACKGROUND Vaccines have emerged as a crucial tool in combatting the COVID-19 pandemic particularly those based on SARS-CoV-2 S-protein mRNA. A crucial aspect of vaccine efficacy is the duration of antibody responses. In this study, a seroconversion panel was created to assess antibody responses to the mRNA-1273 vaccine over time (6.5 months). METHODS Blood samples collected from 15 healthy adult participants prior to and up to 6.5 months after vaccination with the mRNA-1273 vaccine (Moderna). Serum from these blood samples were analyzed for anti-SARS-CoV-2 antibody activity by chemiluminescent immunoassay. RESULTS The immunoassay results showed that one participant was positive for anti-SARS-CoV-2 antibodies prior to vaccination indicating a prior infection. All participants showed a positive antibody response after the first vaccination. Highest antibody responses were seen after the second dose (41-45 days from the first dose). Subsequent samples collected at 69-75 days, 130-135 days, and 221-229 days after the first vaccination showed positive responses but a biphasic decline in the levels of anti-SARS-CoV-2 antibodies. CONCLUSIONS Declining antibody levels in these participants support the use of booster vaccination to increase antibody levels 4-6 months after the initial vaccine series and continued monitoring to assess the durability of COVID-19 vaccine responses. These results are in agreement with other studies showing antibody persistence but declining the antibody levels in the months after immunization with mRNA-based vaccines. The seroconversion panels described here could be useful in the development of antibody assays and in the assessment of the duration of antibody responses to vaccine boosters compared to the initial vaccine series. This panel could also be used to assess antibody activity against emerging viral variants (eg B.1.1.529 [Omicron] and its subvariants) compared to earlier variants.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Plasmatology HEMATOLOGY-

CiteScore

1.10

自引率

0.00%

发文量